Vancomycin therapy for gram-positive peritonitis in patients on CAPD

Area of Science:

• Nephrology
• Infectious Diseases
• Pharmacology

Background:

• Peritonitis is a common complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
• Gram-positive bacteria are frequent causative agents of peritonitis in CAPD patients.
• Effective antibiotic therapy is crucial for managing peritonitis and preventing complications.

Purpose of the Study:

• To compare the efficacy of two vancomycin administration routes for treating gram-positive peritonitis in CAPD patients.
• To evaluate intraperitoneal (IP) versus intravenous (IV) vancomycin therapy.
• To assess treatment outcomes including symptom remission, dialysate clearance, and recurrence rates.

Main Methods:

• A randomized study involving 40 episodes of gram-positive peritonitis in CAPD patients.
• Group A received intraperitoneal vancomycin (30 mg/l for 10 days).
• Group B received intravenous vancomycin (1g on diagnosis and 7 days later).

Main Results:

• Clinical symptom remission occurred within 49-72 hours in both groups.
• Macroscopic clearing of dialysate and negative cultures were observed in 4-7 days for both treatment arms.
• Peritonitis recurrence was noted in 4 patients (20%) in the IV group, occurring two weeks after the second dose.

Conclusions:

• Vancomycin is highly effective in treating gram-positive peritonitis in CAPD patients, irrespective of administration route.
• The intraperitoneal route demonstrated slightly better outcomes with no observed recurrences in this study.
• Intravenous vancomycin, while effective, showed a higher recurrence rate and may be suitable for outpatient management.